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PCSK9 Inhibitors: A Novel Class of Pharmacotherapy
for Hypercholesterolemia
Angela Chu, Austin Hilverding, Elizabeth Kramer, Brendan Rasor, Boyd Rorabaugh, BS, M.S., Ph.D.

This knowledge-based activity is targeted for all pharmacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

ACPE Universal Activity Number (UAN): 0048-0000-16-006-HOI-P
To complete the continuing education program and receive
credit, please go to www.raabecollegeofpharmacy.org/PAW/.

Objectives
After completion of this program, the reader should be able to:
1. Describe the mechanism of action of PCSK9 inhibitors.
2. Identify FDA approved indications for alirocumab
(Praluent®) and evolocumab (Repatha®).
3. Review clinical trials involving PCSK9 inhibitors and
identify potential adverse effects and significant
clinical outcomes.
4. Explain the appropriate storage, use and administration of PCSK9 inhibitors for patient discussion.
Abstract
The recent U.S. Food and Drug Administration (FDA) approval of two new drugs, alirocumab (Praluent®) and evolocumab (Repatha®) is a breakthrough in the treatment of
familial hypercholesterolemia. These drugs are a part of a
new class called the proprotein convertase subtilisin/kexin
type 9 (PCSK9) inhibitors that act by increasing the number
of low density lipoprotein receptors (LDL-R) recycled to
hepatocyte membranes. The increased density of LDL-R facilitates greater clearance of low density lipoproteins from the
blood. Numerous clinical trials have demonstrated the efficacy of these agents, particularly for patients in whom standard
cholesterol-lowering therapy is insufficient. However, data
on long-term health outcomes in patients on PCSK9 inhibitors will not be known for several years. Opportunities for
pharmacists include counseling on how to store and administer the medication, helping patients receive access to therapy
and advocating for healthy lifestyle changes. Pharmacists
should also be aware of insurance coverage and emerging
indications for each agent in order to provide the best care
for patients.
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Introduction
Today's healthcare environment is dominated with concerns
relating to obesity and high cholesterol. The current mainstays of therapy for these conditions are decades old and do
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not provide many patients with sufficient benefit to maximally reduce associated morbidity and mortality. Novel agents
that affect lipid levels are necessary to improve outcomes,
not only in patients with hyperlipidemia associated with a
sedentary lifestyle and poor dietary habits, but also in patients with genetic conditions such as heterozygous and homozygous familial hypercholesterolemia (HeFH, HoFH).
Many of these patients fail to reach or maintain sufficient
reductions in cholesterol levels on standard lipid-lowering
therapies, leading to increased morbidity and mortality. A
new class of lipid-lowering agents, the proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors, are able to induce
significant reductions in low-density lipoprotein cholesterol
(LDL-C) relative to statins and ezetimibe.1.2 This article seeks
to describe the mechanism and efficacy of these new agents
as well as their future role in the management of patients
with hypercholesterolemia.

Pharmacology
Both low density lipoprotein receptors (LDL-R) and PCSK9
are synthesized in hepatocytes under sterol regulatory
element-binding protein 2.3.4 The N-terminus of PCSK9, responsible for proper folding of the enzyme, is cleaved in the
endoplasmic reticulum, but remains attached to PCSK9 in the
catalytic site to inhibit other substrates from binding to it.
The PCSK9 is then packaged and secreted by the golgi apparatus into the plasma, where it can bind LDL-R via the epidermal growth factor domain A (EGF-A). This initiates the
endocytosis and lysosomal degradation of the PCSK9-LDL-R
complex by an unknown mechanism (Figure la). When
PCSK9 is overexpressed, this action results in fewer LDL-R
recycled to the hepatocyte membrane, and a corresponding
increase in LDL-C levels.
Alirocumab and evolocumab are monoclonal antibodies that
bind to PCSK9 to inhibit its binding to the LDL-R (Figure lb).
They also allow the receptor to be recycled back to the surface of the hepatocyte membrane. Both drugs have been approved for the treatment of familial hypercholesterolemia
and clinical atherosclerotic cardiovascular disease (ASCVD),
in addition to a low fat diet and maximally tolerated statin
therapy.s.6 Both drugs have shown superior efficacy and safety profiles compared to the standard treatment, which includes a high dose statin (atorvastatin 80 mg or rosuvastatin
40 mg), ezetimibe and/or niacin with a low fat diet.7
In patients with familial hypercholesterolemia, LDL-C levels
are commonly uncontrolled with high dose statins and adjunct therapy with a second cholesterol lowering agent,
therefore, morbidity and mortality remain high. Statins work
to inhibit cholesterol synthesis, but only modestly reduce
LDL-C levels in some patients. Ezetimibe inhibits cholesterol
absorption in the small intestine via inhibition of the Nie-
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concomitant statin and other lipid-lowering therapy, if applicable, throughout the study. Follow ups were conducted at
weeks 12, 24, 52 and 78 to assess safety and adherence and
to perform lab tests to determine the efficacy of the drug. The
primary endpoint was the change in calculated LDL-C levels
from baseline to week 24. Safety endpoints were adverse
events, including symptoms and laboratory abnormalities
occurring up to week 10.
At week 24, the mean percentage change in calculated LDL-C
levels were -61.0 percent for the alirocumab group versus
0.8 percent in the placebo group (p <0.001).1 The mean absolute LDL-C level at week 24 was 48.3±0.9 mg/dL and
119±1.2 mg/dL in the alirocumab and placebo groups, respectively. Investigators also found that 79.3 percent of patients in the alirocumab group met the goal LDL-C level of
less than 70 mg/dL versus only 8 percent of patients in the
placebo group (p <0.001). Reduction of the LDL-C levels in
the alirocumab group persisted through the end of the trial.

Figure 1.
(a) Proprotein convertase subtilisin/kexin type 9 (PCSK9)
normally binds to the low density lipoprotein receptor
(LDL-R) to induce its endocytosis and lysosomal degradation when LDL binds to the LDL-R.
(b) Evolocumab or alirocumab binds to PCSK9 extracellularly to inhibit PCSK9 from binding to the LDL-R.

mann-Pick Cl-Like 1 transporter to prevent cholesterol from
reaching the hepatic circulation.a Statins and ezetimibe are
usually prescribed as dual therapy with the option of substituting niacin for ezetimibe. However, the mechanism of
niacin is not well understood, and it is not as commonly prescribed. Newer treatments include Iomitapide, a microsomal
triglyceride transfer protein inhibitor and mipomersen, an
inhibitor of mRNA coding of apolipoprotein B-100. 9 At over
$34,000 and $6,000 per dose, respectively, the costs of
Iomitapide and mipomersen are far greater than either
evolocumab and alirocumab, which each cost about $600 per
dose. 10-13 These newer agents are also not as well studied as
the PCSK9 inhibitors.
Trial Data: Alirocumab
Numerous studies have been conducted that illustrate the
efficacy of PCSK9 inhibitors. The Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients
with Hypercholesterolemia Not Adequately Controlled with
Their Lipid Modifying Therapy (ODYSSEY LONG TERM) trial
examined the efficacy and safety of alirocumab in reducing
lipids and cardiovascular events over a period of 78 weeks. 1
This trial included 2,341 patients who had LDL-C levels of
greater than 70 mg/di, at risk for cardiovascular events and
receiving treatment with statins at the highest tolerated dose
with or without other lipid-lowering therapy. Patients had
coronary heart disease, a disease equivalent in cardiovascular risk. or HeFH.

The mean calculated LDL-C level was 122 mg/dL at baseline,
with a goal LDL-C level of less than 70 mg/dL. 1 Subjects were
randomly assigned to receive 150 mg subcutaneous injection
of alirocumab or placebo every two weeks for 78 weeks with
Winter 2016 Volume 7, Issue 1

The percentage of patients who experienced any adverse
reactions was not found to be statistically significant.1 Most
of the reported reactions were related to pain at the injection
site, or a general allergic reaction. Alirocumab had higher
rates of injection-site reactions, myalgia, neurocognitive
events and ophthalmologic events than placebo. In the alirocumab group, 18. 7 percent of patients reported a serious
adverse event versus 19.5 percent in the placebo group.
However, most of the adverse events leading to subject dropout were not considered serious.
In conclusion, more evidence needs to be collected to determine alirocumab's impact on long-term risk of cardiovascular events. The ongoing trial ODYSSEY OUTCOMES is focused
on providing these long-term cardiovascular outcome data
and is expected to be completed near December of 2017.14.15
Trial Data: Evolocumab
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in
Statin Intolerant Subjects (GAUSS-2) assessed the efficacy
and safety of evolocumab.2 The study included 307 patients
currently receiving no or low-dose statins who had previous
intolerance to two or more statins. Subjects were divided
into four groups with different medication regimens:

Group 1: Evolocumab 140 mg subcutaneous injection
every two weeks with oral placebo.
Group 2: Evolocumab 420 mg subcutaneous injection
every month with oral placebo.
Group 3: Ezetimibe once daily with subcutaneous injection of placebo every two weeks.
Group 4: Ezetimibe once daily with subcutaneous injection of placebo every month.
Primary endpoints were the change in LDL-C levels from
baseline to the mean of weeks 10 and 12. The mean baseline
LDL-C level was 193 mg/dL. Primary safety endpoints included serious adverse events and elevations in hepatic enzymes and creatinine kinase.
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At weeks 10 and 12, the LDL-C reductions from baseline
were 56.1 percent in group 1, 55.3 percent in group 2, 36.9
percent in group 3, and 38.7 percent in group 4. 2 More than
75 percent of the evolocumab-treated patients versus less
than 10 percent of the ezetimibe-treated patients were able
to achieve LDL-C levels of less than 100 mg/dL.
Additionally, this study did not find any significant elevations
in liver enzyme tests or creatinine kinase levels. 2 Adverse
events leading to treatment discontinuation occurred in 8
percent of evolocumab treated patients and 13 percent of
ezetimibe treated patients. Only 6 percent of reported adverse events were considered serious. Myalgia was reported
in 8 percent of evolocumab treated patients and 18 percent
of ezetimibe treated patients. Patients taking low dose
statins were more likely to report myalgia.
RedUction of LDL-C with PCSK9 InhibiTion in HEteRozygous
Familial HyperchOlesteRolemia Disorder (RUTHERFORD-2)
evaluated the effects of PCSK9 inhibition with evolocumab in
subjects with HeFH.16 All 331 patients had a clinical diagnosis of HeFH, had been on a statin with or without other lipidlowering therapy for at least 4 weeks prior to the study and
had a fasting LDL-C concentration of 2.6 mmol/L (100 mg/
di) or higher. The dosing was similar to the GAUSS-2 trial,
except evolocumab was compared to placebo alone as shown
in the following groups:
·
Group 1: Evolocumab 140 mg subcutaneous injection
every two weeks.
Group 2: Evolocumab 420 mg subcutaneous injection
every month.
Group 3: Subcutaneous injection of placebo every two
weeks.
Group 4: Subcutaneous injection of placebo every month.
The primary endpoints were percentage change in plasma
LDL-C from baseline to the mean of weeks 10 and 12, and to
week 12. At the mean of weeks 10 and 12, patients in group 1
saw a mean reduction in LDL-C of 60.2 percent (p <0.0001).
Group 2 saw a mean reduction of LDL-C levels of 65.6 percent (p<0.0001). Also, rates of adverse events were similar to
those seen in previous studies of evolocumab. Investigators
did not see any serious adverse events that led to discontinuation of the study drug.
Evolocumab received additional approval for use in HoFH
due to results from Trial Evaluating PCSK9 Antibody in Subjects with LDL-C Receptor Abnormalities (TESLA).6 The ongoing trial Further Cardiovascular Outcomes Research with
PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)
will provide additional information regarding the long-term
efficacy of evolocumab plus statin therapy, and its overall
impact on cardiovascular risks.17

Impact on Healthcare
Long-term data on the effects of PCSK9 inhibitors is several
years away, but there is reason to believe that lowering patient LDL-C levels will improve a broad range of cardiovascular outcomes. Despite increasing research in the area, high
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cholesterol remains one of the largest nationwide health concerns with reports as recent as 2010 estimating that nearly
57 million adults in the United States have hypercholesterolemia.1s The PCSK9 inhibitors will likely serve as efficacious
adjuncts to statin therapy for those with FH or ASCVD. Furthermore, these drugs may potentially be useful as monotherapy for patients who cannot use or tolerate statins. While
some patients may be deterred by having to inject the medication, these agents are proposed as high-compliance formulations. Two administrations per month from autoinjectors
or prefilled syringes may be sufficient for therapy.19,20
Yet, there are numerous challenges healthcare professionals
may face as they try to provide these medications to their
patients. One of the greatest barriers to accessing PCSK9 inhibitors is cost. Upon approval of alirocumab, Sanofi-Regeneron announced a wholesale acquisition cost (WAC) of $40 a
day, or $14,600 a year.s.19 Subsequent approval of the competitor, evolocumab, was projected to considerably reduce
the price of alirocumab, but Amgen announced the WAC at
$14,100 a year. 20 Although the WAC does not include discounts or rebates, and serves merely as an estimate of the
manufacturer's list price, each drug has entered the market
well beyond its projected annual costs of $7,000 to
$12,000.19 Pharmacy benefit managers note that unlike many
monoclonal antibodies used for terminal or curable diseases,
PCSK9 inhibitors are currently indicated for indefinite use,
and future pending studies could see routine use as a replacement for statins. 20 Approximately 71 million Americans
at least 20 years of age have LDL-C levels that are borderline
high or greater (> 13 0 mg/ dL ).1B Millions more have a history
of coronary artery disease or previous cardiac event, suggesting that a wide range of patients beyond those with FH
and ASCVD may benefit from PCSK9 inhibitors. Therefore,
high healthcare costs may be a consequence of these medications if prices remain elevated.

Role of the Pharmacist
With the emergence of PCSK9 inhibitors, pharmacists have
many opportunities for patient education. Patients prescribed these medications should be educated on proper
aseptic and subcutaneous injection technique and disposal of
used drug delivery devices. The most common adverse
events leading to discontinuation in clinical trials included
general allergic reactions, elevated liver enzymes and neurocognitive events. Other minor side effects include pain or
irritation at the site of injection as well as flu-like symptoms.
Patients should be counseled that rotating injection sites may
help reduce skin irritation. As with all monoclonal antibodies, there is a potential for immunogenicity. Praluent®
(alirocumab) and Repatha® (evolocumab) syringes should
be stored under refrigeration and allowed to warm at room
temperature approximately 30 minutes before use.21,22 All
storage, packaging and patient information provided by the
manufacturers should be closely followed.
Additionally, pharmacy benefit managers that pay for these
high-priced pharmaceuticals want evidence of efficacy and
patient compliance to justify the use of PCSK9 inhibitors.
They will likely require regular patient follow-up visits with
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their prescriber and routine monitoring to determine
baseline LDL-C levels. Pharmacists can assist patients in
managing trips to multiple physicians, adherence to a list of
medications and maintaining necessary lifestyle modifications. Engaging patients in comprehensive medication
reviews and medication therapy management services will
further improve adherence rates and overall patient
outcomes. 23

9.

10.

11.

12.

Patient assistance programs are currently available for those
seeking financial support to cover the costs of these medications. Pharmacists can help patients acquire this information
online at www.praluenthcp.com and www.repathahcp.com
or by calling the support phone lines listed on each website.
Conclusion
The PCSK9 Inhibitors are a novel and highly efficacious class
of lipid-lowering medications. These monoclonal antibodies
facilitate the removal of LDL-C from the blood and have
demonstrated superior changes from baseline compared to
both placebo and standard lipid-lowering therapy. Neither
alirocumab nor evolocumab are approved as monotherapy
or first-line therapy, and trials on long-term cardiovascular
outcomes are ongoing. While they have been on the market
for only a few months, there is already much debate regarding the high financial costs and potential ramifications of
these increasingly prescribed drugs. Despite this, the PCSK9
inhibitors present a new and efficacious pharmacotherapeutic option for patients with hypercholesterolemia.
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Assessment Questions
1.

To what does proprotein convertase subtilisin/kexin
type 9 bind?
A. Epidermal growth factor domain A
B. Low density lipoprotein cholesterol
C. Hepatocyte membrane
D. Apolipoprotein 8-100

2.

Inhibition ofproprotein convertase subtilisin/kexin
type 9 leads to increased recycling of
?
A. cholesterol
B. triglycerides
C. low density lipoprotein receptor
D. hepatocytes

3.

Alirocumab (Praluent®) is FDA approved to treat which
conditions?
A. Familial hypercholesterolemia
B. Atherosclerotic cardiovascular disease
C. Hypertension
D. Both A and B

4.

What is an additional approved indication for evolocumab (Repatha®)?
A. Homozygous Familial Hypercholesterolemia
B. Heterozygous Familial Hypercholesterolemia
C. Clinical atherosclerotic cardiovascular disease
D. Monotherapy treatment of hypercholesterolemia

5.

What new information not addressed in completed clinical trials of PCSK9 inhibitors will be provided by the
FOURIER and ODYSSEY OUTCOMES trials?
A. Safety data
B. Cardiovascular risk reduction data
C. Efficacy of PCSK9 inhibitors with concomitant
statin therapy
D. Adverse effects when co-administered with
ezetimibe

6.

Which side effects were observed at a higher rate in the
treatment group versus placebo group in the ODYSSEY
LONG TERM trial?
A. Myalgia and nausea
B. Myalgia, neurocognitive effects and ophthalmologic events
C. Injection site reactions, allergic reactions and GI
upset
D. Anaphylaxis requiring study discontinuation

8.

Which of the following is an advantage to therapy with
PCSK9 inhibitors?
A. It is approved as monotherapy for patients with
familial hypercholesterolemia.
B. Dosing is once or twice monthly, which could
improve adherence.
C. Marked decreases in low density lipoprotein
cholesterol for most patients.
D. Both B and C.

9.

What is a concern associated with long-term administration of monoclonal antibodies such as alirocumab
(Praluent®) and evolocumab (Repatha®)?
A. lmmunogenicity
8. A paradoxical increase in low density lipoprotein cholesterol
C. Poor drug bioavailability
D. Complex dosing regimens

10. Which of the following is an important step in the administration of alirocumab (Praluent®)?
A. Keep injector pen frozen until ready to use.
B. Patients should be counseled on proper intramuscular administration.
C. Allow pen or syringe to warm at room temperature for 30 minutes prior to administration.
D. Thoroughly shake the pen or syringe prior to
use.
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Ohio Northern University is accredited by the
Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education. This
program is eligible for credit until 2/9/2019.

To complete the continuing education program and receive
credit, please go to www.raabecollegeofpharmacy.org/PA W/
to enter the required information. Please allow two to three
weeks for electronic distribution of your continuing education certificate, which will be sent to your valid email address
in PDF format.

7. Of the following options, which is the greatest barrier in
preventing patient access to PCSK9 inhibitors?
A. Compliance issues
B. Lack of drug effectiveness data
C. High medication costs
D. Low product supply
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